Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
WHO. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (2021).
Carreño, J. M. et al. Nature https://doi.org/10.1038/d41586-021-03846-z (2022).
Cao, Y. et al. Nature https://doi.org/10.1038/d41586-021-03796-6 (2022).
Wang, Y. et al. Emerg. Microbes Infect. 11, 1–5 (2022).
Dejnirattisai, W. et al. Cell 185, 467–484 (2022).
Liu, Z. et al. Signal. Transduct. Target Ther. 27, 282 (2022).
Liu, Z. et al. Cell Res. https://doi.org/10.1038/s41422-022-00612-2 (2022).
Huang, J. et al. Immunity. 45, 1108–1121 (2016).
Acknowledgements
This work was supported by the National Natural Science Foundation of China (92169112 to S.J.; 82041036 to L.L.); the Health and Medical Research Fund (COVID1903010 – Project 7 to J.F.-W.C.), The Government of the Hong Kong Special Administrative Region; Health@InnoHK, Innovation and Technology Commission, The Government of the Hong Kong Special Administrative Region (to K.-Y.Y.); the National Key Research and Development Programme on Public Security Risk Prevention and Control Emergency Project (to K.-Y.Y.); the National Program on Key Research Project of China (2020YFA0707500 and 2020YFA0707504 to J.F.-W.C; 2021YFC2300703 to L.L.); the National Key R&D Program of China (2021YFC2300703 to L.L.); Program of Shanghai Academic/Technology Research Leader (20XD1420300 to L.L.). and China Postdoctoral Science Foundation (2021M700840 to Z.L.).
Author information
Authors and Affiliations
Contributions
L.L. and S.J. conceived the idea; L.L., S.J., K.-Y.Y., and Y.W. supervised the project; Z.L., J.F.-W.C., J.Z., M.W., G.Z. and K.K.-H. C. performed the experiments; Y.Z. provided CF501; Z.L. J.F.-W.C., Q.W., and W.X. analyzed the data; Z.L., L.L., S.J. wrote the manuscript; K.-Y.Y., J.F.-W.C., Y.W. and Y.Z. revised the manuscript.
Corresponding authors
Ethics declarations
Competing interests
L.L., S.J., Z.L, J.Z., W.X., Q.W. and Y.Z. filed a patent application for the STING agonist of CF501. J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. Other authors declare that they have no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Liu, Z., Chan, J.FW., Zhou, J. et al. A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Res 32, 495–497 (2022). https://doi.org/10.1038/s41422-022-00631-z
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41422-022-00631-z
